Deals this week: Hybio Pharmaceutical, Pfizer, Bushu Pharmaceuticals

Chinese peptide pharmaceutical company Hybio Pharmaceutical plans to raise up to ¥ 1bn ($145.48m) in gross proceeds through a public offering of corporate bonds.

The proceeds are intended to be used for supplementing its working capital and repay loans.

US-based biopharmaceutical company Pfizer has announced four notes offerings to raise €4bn ($4.21bn) in total.

The offerings include floating rate notes due 2019 to raise €1.25bn ($1.32bn), 1% notes due 2027 for gross proceeds of €750m ($793.47m), 0.25% notes due 2022 for gross proceeds of €1bn ($1.05bn) and notes due 2020 to raise €1bn ($1.05bn).

The proceeds are intended to be used for general corporate purposes and to partially repay its outstanding commercial paper.

Japanese contract manufacturer of pharmaceuticals Bushu Pharmaceuticalshas reached an agreement with Takeda Pharmaceutical Company to acquire the latter’s pharmaceutical sciences / chemistry, manufacturing and controls (CMC) business.

"US-based biopharmaceutical company Pfizer has announced four notes offerings to raise €4bn ($4.21bn) in total."

The acquirer company aims to expand its business services scope through the acquisition, which will enable it to transform from a contract manufacturer to a full-range drug development service provider.

Japanese pharmaceutical companies Astellas Pharma and Lupin’s subsidiary Kyowa Pharmaceutical Industry have announced an agreement, under which the latter will distribute and promote the former’s quetiapine fumarate extended-release tablets in Japan.

The drug is currently under review in Japan for the indication of improvement of depressive symptoms associated with bipolar disorder.

Kyowa will be the exclusive distributor and promoter of the drug once it has been approved by the Japanese Ministry of Health, Labour and Welfare.

Grail has raised $900m in a series B financing round and intends to raise additional funds in second tranche of series B financing round from qualified investors to raise combined gross proceeds of more than $1bn by the first quarter of this year.

Based in the US, Grail provides cancer screening services from a simple blood test.